Analyst Ratings For Alliqua BioMedical (NASDAQ:ALQA)
Today, HC Wainwright reiterated its Buy rating on Alliqua BioMedical (NASDAQ:ALQA) with a price target of $1.50.
There are 3 buy ratings on the stock.
The current consensus rating on Alliqua BioMedical (NASDAQ:ALQA) is Buy (Score: 3.00) with a consensus target price of $1.42 per share, a potential 305.81% upside.
Some recent analyst ratings include
- 9/18/2017-HC Wainwright Reiterated Rating of Buy.
- 4/11/2017-Cowen and Company Reiterated Rating of Outperform.
Recent Insider Trading Activity For Alliqua BioMedical (NASDAQ:ALQA)
Alliqua BioMedical (NASDAQ:ALQA) has insider ownership of 15.80% and institutional ownership of 21.68%.
- On 4/3/2017 Bradford Barton, COO, bought 75,000 with an average share price of $0.40 per share and the total transaction amounting to $30,000.00. View SEC Filing
- On 4/3/2017 David Ian Johnson, Insider, bought 250,000 with an average share price of $0.40 per share and the total transaction amounting to $100,000.00. View SEC Filing
- On 4/3/2017 Mark T Wagner, Director, bought 62,500 with an average share price of $0.40 per share and the total transaction amounting to $25,000.00. View SEC Filing
- On 2/27/2017 Corp /De/ Celgene, Major Shareholder, bought 4,000,000 with an average share price of $0.50 per share and the total transaction amounting to $2,000,000.00. View SEC Filing
- On 2/27/2017 Jerome B Zeldis, Director, bought 400,000 with an average share price of $0.50 per share and the total transaction amounting to $200,000.00. View SEC Filing
- On 11/9/2015 Brian M Posner, CFO, bought 5,000 with an average share price of $3.04 per share and the total transaction amounting to $15,200.00. View SEC Filing
- On 11/6/2015 Bradford Barton, COO, bought 5,000 with an average share price of $2.97 per share and the total transaction amounting to $14,850.00. View SEC Filing
Recent Trading Activity for Alliqua BioMedical (NASDAQ:ALQA)
Shares of Alliqua BioMedical closed the previous trading session at with shares trading hands.